Vinva Investment Management Ltd Has $2.58 Million Holdings in CVS Health Co. (NYSE:CVS)

Vinva Investment Management Ltd boosted its stake in shares of CVS Health Co. (NYSE:CVS) by 4.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 58,789 shares of the pharmacy operator’s stock after buying an additional 2,343 shares during the period. Vinva Investment Management Ltd’s holdings in CVS Health were worth $2,583,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Platinum Investment Management Ltd. purchased a new position in CVS Health during the 4th quarter valued at about $89,000. North Forty Two & Co. purchased a new position in CVS Health during the 4th quarter valued at about $354,000. OVERSEA CHINESE BANKING Corp Ltd grew its stake in CVS Health by 92.1% during the 4th quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 34,125 shares of the pharmacy operator’s stock valued at $1,518,000 after acquiring an additional 16,365 shares in the last quarter. Xponance Inc. grew its stake in CVS Health by 2.5% during the 4th quarter. Xponance Inc. now owns 188,834 shares of the pharmacy operator’s stock valued at $8,477,000 after acquiring an additional 4,585 shares in the last quarter. Finally, Generali Asset Management SPA SGR purchased a new position in CVS Health during the 4th quarter valued at about $1,914,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Up 0.4 %

Shares of CVS stock opened at $67.84 on Thursday. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $80.75. The firm has a market cap of $85.53 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 0.98 and a beta of 0.54. The stock has a 50 day moving average of $59.76 and a 200-day moving average of $57.20. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, equities analysts predict that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd were issued a dividend of $0.665 per share. The ex-dividend date was Thursday, January 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.92%. CVS Health’s dividend payout ratio (DPR) is presently 72.68%.

Insider Activity at CVS Health

In other news, Director Michael F. Mahoney bought 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was acquired at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the purchase, the director now owns 39,356 shares of the company’s stock, valued at $2,625,045.20. This trade represents a 320.65 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP James David Clark sold 7,513 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the transaction, the senior vice president now owns 8,394 shares of the company’s stock, valued at $556,941.90. The trade was a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.24% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CVS. Deutsche Bank Aktiengesellschaft raised CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price on the stock in a research note on Tuesday, December 3rd. Piper Sandler lowered their price target on CVS Health from $72.00 to $64.00 and set an “overweight” rating for the company in a research note on Monday, November 25th. UBS Group lowered their price target on CVS Health from $62.00 to $59.00 and set a “neutral” rating for the company in a research note on Tuesday, February 11th. Evercore ISI boosted their price target on CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a research note on Monday, January 27th. Finally, TD Cowen boosted their price target on CVS Health from $73.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, November 25th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, CVS Health currently has an average rating of “Moderate Buy” and a consensus price target of $69.83.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.